Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01048879 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT01048879 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 15 participants.
The verdict
NCT01048879, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Critically ill patients with flu may receive a drug called oseltamivir. They may also receive medical therapies to support their lung function (extracorporeal membrane oxygenation; ECMO) and kidney function (continuous venovenous hemodialysis; CVVHD). CVVHD and ECMO may remove some oseltamivir from the bloodstream. The purpose of this study is to determine how much oseltamivir gets removed by CVVHD or ECMO in critically ill patients.
Interventions
- PROCEDURE pharmacokinetic blood sampling
- PROCEDURE pharmacokinetic blood and dialysate sampling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01048879
The ClinicalTrials.gov registry entry for NCT01048879 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pharmacokinetic blood sampling is the first listed.
NCT01048879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01048879 about?
NCT01048879 is a clinical study titled "Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)". Critically ill patients with flu may receive a drug called oseltamivir. They may also receive medical therapies to support their lung function (extracorporeal membrane oxygenation; ECMO) and kidney function (continuous venovenous hemodialysis; CVVHD). CVVHD and ECMO may remove some oseltamivir from ...
What is the current status of trial NCT01048879?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2009-10. Estimated completion is 2010-01.
What interventions are being tested in trial NCT01048879?
The interventions under investigation include: pharmacokinetic blood sampling (PROCEDURE), pharmacokinetic blood and dialysate sampling (PROCEDURE).
Who is sponsoring clinical trial NCT01048879?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.